Concerning Caspari et al: Pathogen Inactivation of Cellular Blood Products – More Security for the Patient or Less? Transfus Med Hemother 2003;30:261–263

Publisher： Karger

E-ISSN： 1660-3818|32|1|45-48

ISSN： 1660-3796

Source： Transfusion Medicine and Hemotherapy, Vol.32, Iss.1, 2005-01, pp. : 45-48

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pathogen Inactivation of Cellular Blood Products – More Security for the Patient or Less?

By  

Transfusion Medicine and Hemotherapy, Vol. 30, Iss. 6, 2003-12 ,pp. : 261-263

Karger

Access to resources Recommend Favorite

Concerning ‘Hepatitis C Virus’ (Transfus Med Hemother2003;30:239–250)

By  

Transfusion Medicine and Hemotherapy, Vol. 30, Iss. 6, 2003-12 ,pp. : 288-

Karger

Access to resources Recommend Favorite

Concerning Chapter 5 – Human Albumin; in Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives, 4th ed. Transfus Med Hemother 2009;36(6):399–407

By  

Transfusion Medicine and Hemotherapy, Vol. 37, Iss. 2, 2010-03 ,pp. : 98-99

Karger

Access to resources Recommend Favorite

Epidemiology of HIV, HBV and HCV and the Safety of Blood Products. Concerning Stark K, et al: Infections with HIV, HBV and HCV among blood donors in Germany 1998 and 1999. Infus Ther Transfus Med 2002;29:305–307 / Authors' Reply

By  

Transfusion Medicine and Hemotherapy, Vol. 30, Iss. 3, 2003-06 ,pp. : 144-145

Karger

Access to resources Recommend Favorite

Concerning Hänecke P, Klouche M: ThrombelastographyToday: Practicability and Analytical Power. Transfus Med Hemother 2007;34:421–428

By  

Transfusion Medicine and Hemotherapy, Vol. 35, Iss. 4, 2008-07 ,pp. : 324-326

Karger

Access to resources Recommend Favorite